BR100 Increased By (0.75%)
BR30 Increased By (1.08%)
KSE100 Increased By (0.82%)
KSE30 Increased By (0.89%)
AGHA 6.42 Increased By ▲ 0.04 (0.63%)
BECO 4.32 Decreased By ▼ -0.03 (-0.69%)
BML 62.90 Increased By ▲ 0.35 (0.56%)
BOP 31.50 Increased By ▲ 0.11 (0.35%)
CNERGY 11.89 Increased By ▲ 0.16 (1.36%)
CSIL 5.86 Decreased By ▼ -0.05 (-0.85%)
FCCL 62.30 Increased By ▲ 0.59 (0.96%)
FFL 14.86 Increased By ▲ 0.07 (0.47%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.36 Increased By ▲ 0.04 (0.63%)
KOSM 5.85 Decreased By ▼ -0.05 (-0.85%)
LOTCHEM 24.71 Increased By ▲ 0.02 (0.08%)
MLCF 106.30 Increased By ▲ 2.37 (2.28%)
NBP 174.59 Increased By ▲ 1.27 (0.73%)
NCPL 52.40 Increased By ▲ 0.57 (1.1%)
NPL 55.00 Increased By ▲ 0.97 (1.8%)
OGDC 320.61 Increased By ▲ 4.74 (1.5%)
PACE 9.34 Increased By ▲ 0.08 (0.86%)
PAEL 35.82 Increased By ▲ 0.24 (0.67%)
PIBTL 13.86 Increased By ▲ 0.20 (1.46%)
PPL 228.70 Increased By ▲ 2.63 (1.16%)
PRL 81.99 Increased By ▲ 1.71 (2.13%)
PTC 47.14 Increased By ▲ 0.50 (1.07%)
SSGC 24.00 Increased By ▲ 0.18 (0.76%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.54 Decreased By ▼ -0.01 (-0.13%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.13 Increased By ▲ 0.14 (1.08%)
TREET 26.11 Increased By ▲ 0.13 (0.5%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)
World

Britain approves J&J COVID-19 vaccine for use

  • Britain also cut its order for the single-dose shot, also known as J&J unit Janssen's vaccine, amid issues with the company's supply chain and reports of rare blood clots.
  • J&J's vaccine is already approved in the United States and European Union, where reports of rare blood clots are being reviewed.
Published Updated
By

LONDON: Britain's medicine regulator has approved Johnson & Johnson's COVID-19 vaccine for use, the health ministry said in a statement on Friday, making it the fourth COVID-19 shot available for use in the country.

Britain also cut its order for the single-dose shot, also known as J&J unit Janssen's vaccine, amid issues with the company's supply chain and reports of rare blood clots.

Britain has given two-thirds of the population a first dose of COVID-19, and the government cited the "unprecedented scale and pace" of the roll-out as behind the decision to cut its order to 20 million doses from the original order for 30 million doses.

"As Janssen is a single-dose vaccine, it will play an important role in the months to come as we redouble our efforts to encourage everyone to get their jabs and potentially begin a booster programme later this year," health minister Matt Hancock said.

J&J's vaccine is already approved in the United States and European Union, where reports of rare blood clots are being reviewed.

The shot uses similar viral vector technology to the Oxford-AstraZeneca vaccine, where similar clots have been reported.

Britain has advised that under-40s are offered an alternative to the AstraZeneca shot, and the government said that vaccine advisers the Joint Committee on Vaccination and Immunisation (JCVI) would also advise on how J&J's shot was used.

The government said the shot would be available later in the year. There have been reports that J&J expects to miss its delivery targets for the European Union this quarter.

Comments

Comments are closed for this article.